Table 1.

Within-study characteristics of 18 patients with human immunodeficiency virus type 1 (HIV-1) infection

Patient characteristic
Patient ID	Sex	Age	Number of samplings	Antiretroviral therapy	CD4+cell count(cells/µl)	Viral load(copies/µl)	Community periodontal index
A	Male	36	2	TDF/FTC + ATV/r	8–18	13000–50000	2.33–2.16
B	Male	48	3	AZT/3TC + EFV	481–536	<40–110	0.00–0.67
C	Male	29	4	ABC/3TC + ATV/r	108–247	<40–110	1.66–2.00
D	Male	36	1	ABC/3TC + ATV/r	466	45	2.00
E	Male	58	3	ABC/3TC + LPV/r	183–291	<40–300	0.83–2.67
F	Female	26	1	AZT/3TC + LPV/r	446	<40	0.83
G	Female	41	1	AZT/3TC + LPV/r	320	<40	1.50
H	Male	41	5	ABC/3TC + ATV/r	258–406	<40–300	0.67–1.67
I	Male	42	1	ABC/3TC + LPV/r	365	<40	0.83
J	Male	48	2	d4T + 3TC + LPV/r	206–238	<40–44	0.50–1.60
K	Male	39	4	AZT + TDF + LPV/r	300–505	<40–50	0.00–2.17
L	Female	32	1	TDF/FTC + LPV/r	144	1300	0.67
M	Male	38	2	TDF/FTC + EFV	268–417	<40–15000	2.50–2.70
N	Female	32	5	TDF/FTC + ATV	81–224	Not detected to <40	1.00–2.00
O	Male	33	6	Untreated	286–388	1600–8600	0.00–1.00
P	Male	32	1	ABC/3TC + LPV/r	172	<40	2.00
Q	Male	60	1	TDF/FTC + ATV/r	42	1600	2.80
R	Male	31	1	Untreated	651	7300	1.17

Data presented as value or range.

ID, patient study identification; AZT, zidovudine; d4T, stavudine; ABC, abacavir; 3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; ATV, atazanavir; LPV, lopinavir; r, ritonavir for boosting.